Name
HansaBioMed Life Sciences OÜ
Registry code
12993514
VAT number
EE101867663
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
10.02.2016 (8)
Financial year
01.01-31.12
Capital
102 516.00 €
Activity
47991 - Other retail sale not in stores, stalls or markets 72111 - Research and experimental development on biotechnology
783 425 €
339 357 €
43%
2 129 €
(estimate is approximate)
1 036 006 €
10
Submitted
No tax arrears
33%
25%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Antonio Chiesi 02.01.1959 (65) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member | |
| Paolo Guazzi 19.09.1978 (46) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member | |
| BioBalt Holding OÜ 11393103 | - | - | - | Founder |
| 2019 22.06.2020 | 2020 14.09.2021 | 2021 25.07.2022 | 2022 23.08.2023 | 2023 01.04.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 410 901 € | 363 801 € | 495 968 € | 511 483 € | 783 425 € |
| Net profit (loss) for the period | 117 615 € | 40 745 € | 196 227 € | 215 066 € | 339 357 € |
| Profit Margin | 29% | 11% | 40% | 42% | 43% |
| Current Assets | 610 649 € | 682 041 € | 561 620 € | 606 861 € | 1 215 086 € |
| Fixed Assets | 329 819 € | 717 088 € | 731 953 € | 411 054 € | 125 616 € |
| Total Assets | 940 468 € | 1 399 129 € | 1 293 573 € | 1 017 915 € | 1 340 702 € |
| Current Liabilities | 61 902 € | 315 206 € | 222 700 € | 223 714 € | 216 405 € |
| Non Current Liabilities | 633 900 € | 798 512 € | 589 235 € | 97 497 € | 88 291 € |
| Total Liabilities | 695 802 € | 1 113 718 € | 811 935 € | 321 211 € | 304 696 € |
| Share Capital | - | - | - | - | - |
| Equity | 244 666 € | 285 411 € | 481 638 € | 696 704 € | 1 036 006 € |
| Employees | 9 | 11 | 11 | 10 | 10 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 160 852.1 € | 32 034.76 € | 33 730.29 € | 9 |
| 2023 Q4 | 271 145.83 € | 31 513.66 € | 33 401 € | 9 |
| 2023 Q3 | 203 990.91 € | 34 026.72 € | 36 099.56 € | 9 |
| 2023 Q2 | 211 040.82 € | 33 800.5 € | 36 021.07 € | 10 |
| 2023 Q1 | 226 879.79 € | 32 427.31 € | 34 236.35 € | 10 |
| 2022 Q4 | 175 321.1 € | 34 649.88 € | 36 822.79 € | 11 |
| 2022 Q3 | 130 119.7 € | 35 174.43 € | 37 178.23 € | 11 |
| 2022 Q2 | 142 953.19 € | 35 528.94 € | 37 810.01 € | 11 |
| 2022 Q1 | 174 890.49 € | 35 761.43 € | 37 827.73 € | 12 |
| 2021 Q4 | 149 772.45 € | 35 842.36 € | 38 100.43 € | 13 |
| 2021 Q3 | 161 958.7 € | 36 843.02 € | 39 146.07 € | 13 |
| 2021 Q2 | 116 871.33 € | 34 351.12 € | 36 707.79 € | 13 |
| 2021 Q1 | 142 020.08 € | 33 368.08 € | 35 695.32 € | 12 |
| 2020 Q4 | 139 311.02 € | 30 296.08 € | 32 363.82 € | 11 |
| 2020 Q3 | 100 946.53 € | 25 510.46 € | 27 229.5 € | 10 |
| 2020 Q2 | 73 518.88 € | 23 547.89 € | 25 150.56 € | 10 |
| 2020 Q1 | 168 530.81 € | 28 762.82 € | 29 566.33 € | 10 |
